Natural Killer Cell Diversity in Viral Infection: Why and How Much?

Article Sidebar

HTML PDF
Published: Aug 31, 2016
DOI: https://doi.org/10.20411/pai.v1i1.142
Keywords:
NK cell or natural killer cell, virus, diversity, repertoire, lymphocyte, mass cytometry

Main Article Content

Catherine A. Blish
Department of Medicine, Division of Infectious Diseases and Geographic Medicine; Immunology Program, Stanford University School of Medicine, Stanford, CA

Abstract

Natural killer cells are a diverse group of innate lymphocytes that are specialized to rapidly respond to cancerous or virus-infected cells. NK cell function is controlled by the integration of signals from activating and inhibitory receptors expressed at the cell surface. Variegated expression patterns of these activating and inhibitory receptors at the single cell level leads to a highly diverse NK cell repertoire. Here I review the factors that influence NK cell repertoire diversity and its functional consequences for our ability to fight viruses.

Downloads

Download data is not yet available.

Article Details

Issue
Vol. 1 No. 1: Volume 1, Number 1
Section
Reviews

Pathogens and Immunity abides by Creative Commons BY 4.0:

http://creativecommons.org/licenses/by/4.0/

This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.

*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.   

Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975;16(2):216–29. PubMed PMID: 50294.
  2. Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5(2):112–7. PubMed PMID: 1234049. doi: 10.1002/eji.1830050208
  3. Rankin L, Groom J, Mielke LA, Seillet C, Belz GT. Diversity, function, and transcriptional regulation of gut innate lymphocytes. Frontiers in immunology. 2013;4:22. PubMed PMID: 23508190. Pubmed Central PMCID: 3600536. doi: 10.3389/fimmu.2013.00022
  4. Vanherberghen B, Olofsson PE, Forslund E, Sternberg-Simon M, Khorshidi MA, Pacouret S, Guldevall K, Enqvist M, Malmberg K-J, Mehr R, Onfelt B. Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood. 2013;121(8):1326–34. PubMed PMID: 23287857. doi: 10.1182/blood-2012-06-439851
  5. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. The Lancet. 2000;356(9244):1795–9. PubMed PMID: 11117911. doi: 10.1016/S0140-6736(00)03231-1
  6. Borrego F, Larrucea S, Solana R, Tarazona R. Editorial: NK Cell-Based Cancer Immunotherapy. Front Immunol. 2016;7:249. PubMed PMID: 27446079. Pubmed Central PMCID: 4921465. doi: 10.3389/fimmu.2016.00249
  7. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230–52. PubMed PMID: 23604045. Pubmed Central PMCID: 4076738. doi: 10.1038/cmi.2013.10
  8. Berrien-Elliott MM, Romee R, Fehniger TA. Improving natural killer cell cancer immunotherapy. Current Opinion in Organ Transplantation. 2015;20(6):671–80. PubMed PMID: 26414502. Pubmed Central PMCID: 4635041. doi: 10.1097/MOT.0000000000000243
  9. Rezvani K, Rouce RH. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol. 2015;6:578. Pubmed Central PMCID: 4648067. doi: 10.3389/fimmu.2015.00578
  10. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989 Jun 29;320(26):1731–5. PubMed PMID: 2543925. doi: 10.1056/NEJM198906293202605
  11. Eidenschenk C, Dunne J, Jouanguy E, Fourlinnie C, Gineau L, Bacq D, McMahon C, Smith O, Casanova J-L, Abel L, Feighery C. A Novel Primary Immunodeficiency with Specific Natural-Killer Cell Deficiency Maps to the Centromeric Region of Chromosome 8. Am J Hum Genet. 2006;78(4):721–7. PubMed PMID: 16532402. Pubmed Central PMCID: 1424699. doi: 10.1086/503269
  12. Tangye SG, Phillips JH, Lanier LL, Nichols KE. Cutting Edge: Functional Requirement for SAP in 2B4-Mediated Activation of Human Natural Killer Cells as Revealed by the X-Linked Lymphoproliferative Syndrome. J Immunol. 2000;165(6):2932–6. PubMed PMID: 10975798.
  13. Nakajima H. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol. 2000;30(11):3309–18. PubMed PMID: 11093147. doi: 10.1002/1521-4141(200011)30:11<3309:AID-IMMU3309>3.0.CO;2-3
  14. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, Ochs HD, Wolf H, Bonnefoy JY, Biassoni R, Moretta L, Notarangelo LD, Moretta A. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192(3):337–46. PubMed PMID: 10934222. Pubmed Central PMCID: 2193227
  15. Bottino C, Falco M, Parolini S, Marcenaro E, Augugliaro R, Sivori S, Landi E, Biassoni R, Notarangelo LD, Moretta L, Moretta A. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med. 2001;194(3):235–46. PubMed PMID: 11489943. Pubmed Central PMCID: 2193462.
  16. Li F-Y, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood. 2014;123(14):2148–52. PubMed PMID: 24550228. Pubmed Central PMCID: 3975255. doi: 10.1182/blood-2013-11-538686
  17. Paust S, Andrian UHV. Natural killer cell memory. Nat Immunol. 2011;12(6):500–8. PubMed PMID: 21739673.
  18. Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL. NK Cells and Immune “Memory.” The Journal of Immunology. 2011 Feb 2;186(4):1891–7. PubMed PMID: 21289313. Pubmed Central PMCID: 4410097. doi: 10.4049/jimmunol.1003035
  19. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad of Sci USA. 2009;106(6):1915–9. PubMed PMID: 19181844. Pubmed Central PMCID: 2644138. doi: 10.1073/pnas.0813192106
  20. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science. 2011;331(6013):44–9. PubMed PMID: 21212348. Pubmed Central PMCID: 3089969. doi: 10.1126/science.1198687
  21. O Sullivan TE, Sun JC, Lanier LL. Natural Killer Cell Memory. Immunity. 2015;43(4):634–45. PubMed PMID: 26488815. Pubmed Central PMCID: 4621966. doi: 10.1016/j.immuni.2015.09.013
  22. Manser AR, Weinhold S, Uhrberg M. Human KIR repertoires: shaped by genetic diversity and evolution. Immunol Rev. 2015;267(1):178–96. PubMed PMID: 26284478. doi: 10.1111/imr.12316
  23. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334(6181):395–402. PubMed PMID: 3043226. doi: 10.1038/334395a0
  24. Parham P. The genetic and evolutionary balances in human NK cell receptor diversity. Semin Immunol. 2008;20(6):311–6. PubMed PMID: 19036608. Pubmed Central PMCID: 3205964. doi: 10.1016/j.smim.2008.10.002
  25. Parham P. Influence of KIR diversity on human immunity. Adv Exp Med Biol. Boston, MA: Springer US; 2005;560(Chapter 6):47–50. PubMed PMID: 15932019. doi: 10.1007/0-387-24180-9_6
  26. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E. Human NK Cell Education by Inhibitory Receptors for MHC Class I. Immunity. 2006;25(2):331–42. PubMed PMID: 16901727. doi: 10.1016/j.immuni.2006.06.013
  27. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song Y-J, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709–13. PubMed PMID: 16079848. doi: 10.1038/nature03847
  28. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105(11):4416–23. PubMed PMID: 15728129. Pubmed Central PMCID: 1895026. doi: 10.1182/blood-2004-08-3156
  29. Parham P. MHC class I molecules and kirs in human history, health and survival. Nat Rev Immunol. 2005;5(3):201–14. PubMed PMID: 15719024. doi: 10.1038/nri1570
  30. Makrigiannis AP, Parham P. The evolution of NK cell diversity. Semin Immunol. 2008;20(6):309–10. PubMed PMID: 18938087. doi: 10.1016/j.smim.2008.09.004
  31. Goodridge JP, Önfelt B, Malmberg K-J. Newtonian cell interactions shape natural killer cell education. Immunol Rev. 2015;267(1):197–213. PubMed PMID: 26284479. Pubmed Central PMCID: 4832384. doi: 10.1111/imr.12325
  32. Gendzekhadze K, Norman PJ, Abi-Rached L, Graef T, Moesta AK, Layrisse Z, Parham P. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc Natl Acad Sci USA. National Acad Sciences; 2009;106(44):18692–7. PubMed PMID: 19837691. Pubmed Central PMCID: 2774017. doi: 10.1073/pnas.0906051106
  33. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas FH, Walker JJ, Redman CC, Morgan L, Tower C, Regan L, Moore GE, Carrington M, Moffett A. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest. 2010;120(11):4102–10. PubMed PMID: 20972337. Pubmed Central PMCID: 2964995. doi: 10.1172/JCI43998
  34. Hiby SE, Apps R, Chazara O, Farrell LE, Magnus P, Trogstad L, Gjessing HK, Carrington M, Moffett A. Maternal KIR in Combination with Paternal HLA-C2 Regulate Human Birth Weight. J Immunol. 2014;192(11)5069–73. PubMed PMID: 24778445. Pubmed Central PMCID: 4028203. doi: 10.4049/jimmunol.140057
  35. Xiong S, Sharkey AM, Kennedy PR, Gardner L, Farrell LE, Chazara O, Bauer J, Hiby SE, Colucci F, Moffett A. Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation. J Clin Invest. 2013;123(10);4264–72. PubMed PMID: 24091323. Pubmed Central PMCID: 4382274. doi: 10.1172/JCI68991
  36. Moffett A, Colucci F. Co-evolution of NK receptors and HLA ligands in humans is driven by reproduction. Immunol Rev. 2015;267(1):283–97. PubMed PMID: 26284484. doi: 10.1111/imr.12323
  37. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol. Nature Publishing Group; 2013;13(2):133–44. PubMed PMID: 23334245. Pubmed Central PMCID: 3956658. doi: 10.1038/nri3370
  38. Hilton HG, Norman PJ, Nemat-Gorgani N, Goyos A, Hollenbach JA, Henn BM, Gignoux CR, Guethlein LA, Parham P. Loss and Gain of Natural Killer Cell Receptor Function in an African Hunter-Gatherer Population. Tishkoff SA, editor. PLoS Genet. 2015;11(8):e1005439–20. PubMed PMID: 26292085. Pubmed Central PMCID: 4546388. doi: 10.1371/journal.pgen.1005439
  39. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983 Oct;131(4):1789–96. PubMed PMID: 6225799.
  40. Martinet L, De Andrade LF, Guillerey C, Lee JS, Liu J, Souza-Fonseca-Guimaraes F, Hutchinson DS, Kolesnik TB, Nicholson SE, Huntington ND, Smyth MJ. DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation. CellReports. The Authors; 2015;11(1):85–97. PubMed PMID: 25818301. doi: 10.1016/j.celrep.2015.03.006
  41. Di Santo JP. Natural killer cells: diversity in search of a niche. Nat Immunol. 2008;9(5):473–5. PubMed PMID: 18425102. doi: 10.1038/ni.f.201
  42. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–40. 2001;22(11):633–40. PubMed PMID: 11698225.
  43. Angelo LS, Banerjee PP, Monaco-Shawver L, Rosen JB, Makedonas G, Forbes LR, Mace EM, Orange JS. Practical NK cell phenotyping and variability in healthy adults. Immunol Res. 2015;62(3):341–56. PubMed PMID: 26013798. Pubmed Central PMCID: 4470870. doi: 10.1007/s12026-015-8664-y
  44. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, Streeck H, Johnston MN, Staller KD, Zaman MT, Yu XG, Lichterfeld M, Basgoz N, Rosenberg ES, Altfeld M. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood. 2005;106(10):3366–9. PubMed PMID: 16002429. doi: 10.1182/blood-2005-03-1100
  45. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D, Parham P. Genetic control of human NK cell repertoire. J Immunol. 2002;169(1):239–47. PubMed PMID: 12077250.
  46. Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, Parham P. Allelic Polymorphism Synergizes with Variable Gene Content to Individualize Human KIR Genotype. J Immunol. 2002;168(5):2307–15. PubMed PMID: 11859120.
  47. Yawata M. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006;203(3):633–45. PubMed PMID: 16533882. Pubmed Central PMCID: 2118260. doi: 10.1084/jem.20051884
  48. Yawata M, Yawata N, McQueen K, Cheng N, Guethlein L, Rajalingam R, Shilling H, Parham P. Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression. Immunogenetics. 2002;54(8):543–50. PubMed PMID: 12439616. doi: 10.1007/s00251-002-0497-x
  49. Yawata M, Yawata N, Draghi M, Partheniou F, Little A-M, Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood. 2008;112(6):2369–80. PubMed PMID: 18583565. Pubmed Central PMCID: 2532809. doi: 10.1182/blood-2008-03-143727
  50. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, Dekker CL, Mackey S, Maecker H, Swan GE, Davis MM, Norman PJ, Guethlein LA, Desai M, Parham P, Blish CA. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. 2013;5(208):208ra145. PubMed PMID: 24154599. Pubmed Central PMCID: 3918221. doi: 10.1126/scitranslmed.3006702
  51. Bendall SC, Simonds EF, Qiu P, Amir E-AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, Balderas RS, Plevritis SK, Sachs K, Pe’er D, Tanner SD, Nolan GP. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687–96. PubMed PMID: 21551058. Pubmed Central PMCID: 3273988. doi: 10.1126/science.1198704
  52. Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler’s guide to cytometry. Trends Immunol. 2012;33(7):323–32. PubMed PMID: 22476049. Pubmed Central PMCID: 3383392. doi: 10.1016/j.it.2012.02.010
  53. Strauss-Albee DM, Horowitz A, Parham P, Blish CA. Coordinated regulation of NK receptor expression in the maturing human immune system. J of Immunol. 2014;193(10):4871–9. PubMed PMID: 25288567. Pubmed Central PMCID: 4225175. doi: 10.4049/jimmunol.1401821
  54. Strauss-Albee DM, Fukuyama J, Liang EC, Yao Y, Jarrell JA, Drake AL, Kinuthia J, Montgomery RR, John-Stewart G, Holmes S, Blish CA. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci Transl Med. 2015;7(297):297ra115–5. PubMed PMID: 26203083. Pubmed Central PMCID: 4547537. doi: 10.1126/scitranslmed.aac5722
  55. Kay AW, Strauss-Albee DM, Blish CA. Application of Mass Cytometry (CyTOF) for Functional and Phenotypic Analysis of Natural Killer Cells. Methods Mol Biol. 2016;1441:13–26. PubMed PMID: 27177653. doi: 10.1007/978-1-4939-3684-7_2
  56. Manser AR, Uhrberg M. Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance. Cancer Immunol Immunother. Springer Berlin Heidelberg; 2015;65(4):417–26. PubMed PMID: 26288343. doi: 10.1007/s00262-015-1750-0
  57. Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira J, Ribeiro ADS, Falcão RR, Abdelhay E, Bouzas LF, Thuler LCS, Ornellas MH, Diamond HR. Age-related changes in natural killer cell receptors from childhood through old age. Hum Immunol. 2011;72(4):319–29. PubMed PMID: 21262312. doi: 10.1016/j.humimm.2011.01.009
  58. Sundström Y, Nilsson C, Lilja G, Karre K, Troye-Blomberg M, Berg L. The Expression of Human Natural Killer Cell Receptors in Early Life. Scand J Immunol. 2007;66(2-3):335–44. PubMed PMID: 17635811. doi: 10.1111/j.1365-3083.2007.01980.x
  59. Le Garff-Tavernier M, Béziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debré P, Merle-Beral H, Vieillard V. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell. 2010;9(4):527–35. PubMed PMID: 20477761. doi: 10.1111/j.1474-9726.2010.00584.x
  60. Lutz CT, Moore MB, Bradley S, Shelton BJ, Lutgendorf SK. Reciprocal age related change in natural killer cell receptors for MHC class I. Mech Ageing Dev. 2005;126(6-7):722–31. PubMed PMID: 15888327. Pubmed Central PMCID: 3394430. doi: 10.1016/j.mad.2005.01.004
  61. Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M, Yin B, Huang J, Mao L, Lu Y, Sun Z. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol. 2015;45(10):2886–97. PubMed PMID: 26171588. doi: 10.1002/eji.201545480
  62. Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev. 2013;12(4):1069–78. PubMed PMID: 23660515. Pubmed Central PMCID: 4147963. doi: 10.1016/j.arr.2013.04.003
  63. Goodier MR, White MJ, Darboe A, Nielsen CM, Goncalves A, Bottomley C, Moore SE, Riley EM. Rapid NK cell differentiation in a population with near-universal human cytomegalovirus infection is attenuated by NKG2C deletions. Blood. American Society of Hematology; 2014;124(14):2213–22. PubMed PMID: 25150297. Pubmed Central PMCID: 4206953. doi: 10.1182/blood-2014-05-576124
  64. Ma Y, Li X, Kuang E. Viral Evasion of Natural Killer Cell Activation. Viruses. 2016;8(4):95. PubMed PMID: 27077876. Pubmed Central PMCID: 4848590. doi: 10.3390/v8040095
  65. Marras F, Bozzano F, De Maria A. Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol. 2011;2011:152430. PubMed PMID: 21860586. Pubmed Central PMCID: 3155793. doi: 10.1155/2011/152430
  66. Marras F, Bozzano F, Ascierto ML, De Maria A. Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV. Front Immunol. 2014;5(6):305. PubMed PMID: 25071766. Pubmed Central PMCID: 4078246. doi: 10.3389/fimmu.2014.00305
  67. Zingoni A, Ardolino M, Santoni A, Cerboni C. NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. Front Immunol. 2012;3:408. PubMed PMID: 23316196. Pubmed Central PMCID: 3540764. doi: 10.3389/fimmu.2012.00408
  68. Reyburn H, Esteso G, Ashiru O, Vales-Gomez M. Viral strategies to modulate NKG2D-ligand expression in Human Cytomegalovirus infection. New Horizons in Translational Medicine. Elsevier; 2015;2(6-7):159–66. doi: 10.1016/j.nhtm.2015.11.002
  69. Carrillo-Bustamante P, Kesmir C, De Boer RJ. The evolution of natural killer cell receptors. Immunogenetics. 2016;68(1):3–18. PubMed PMID: 26392015. Pubmed Central PMCID: 4701786. doi: 10.1007/s00251-015-0869-7
  70. Cheent K, Khakoo SI. Natural killer cells: integrating diversity with function. Immunology. 2009;126(4):449–57. PubMed PMID: 19278418. Pubmed Central PMCID: 2673357. doi: 10.1111/j.1365-2567.2009.03045.x
  71. Körner C, Altfeld M. Role of KIR3DS1 in human diseases. Front Immunol. 2012;3:326. PubMed PMID: 23125843. Pubmed Central PMCID: 3485674. doi: 10.3389/fimmu.2012.00326
  72. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O’Brien SJ, Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31(4):429–34. PubMed PMID: 12134147. doi: 10.1038/ng934
  73. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD, Telenti A, Connors M, O’Brien SJ, Walker BD, Parham P, Deeks SG, Mcvicar DW, Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007;39(6):733–40. PubMed PMID: 17496894. Pubmed Central PMCID: 4135476. doi: 10.1038/ng2035
  74. López-Vázquez A, Miña-Blanco A, Martínez-Borra J, Njobvu PD, Suárez-Alvarez B, Blanco-Gelaz MA, González S, Rodrigo L, López-Larrea C. Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. HIM. 2005;66(3):285–9. PubMed PMID: 15784466. doi: 10.1016/j.humimm.2005.01.001
  75. Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, Ge D, De Luca A, Martinez-Picado J, Wolinsky SM, Martinson JJ, Jamieson BD, Bream JH, Martin MP, Borrow P, Letvin NL, Mcmichael AJ, Haynes BF, Telenti A, Carrington M, Goldstein DB, Alter G. Copy Number Variation of KIR Genes Influences HIV-1 Control. PLoS Biol. 2011;9(11):e1001208. PubMed PMID: 22140359. Pubmed Central PMCID: 3226550. doi: 10.1371/journal.pbio.1001208
  76. Jennes W, Verheyden S, Mertens JW, Camara M, Seydi M, Dieye TN, Mboup S, Demanet C, Kestens L. Inhibitory KIR/HLA ligand incompatibility between sexual partners confers protection against HIV-1 transmission. Blood. 2013;121(7):1157–64. PubMed PMID: 23243280. doi: 10.1182/blood-2012-09-455352
  77. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, Miller JS, Carrington M, Altfeld M. HLA Class I Subtype-Dependent Expansion of KIR3DS1+ and KIR3DL1+ NK Cells during Acute Human Immunodeficiency Virus Type 1 Infection. J Virol. 2009;83(13):6798–805. PubMed PMID: 19386717. Pubmed Central PMCID: 2698561. doi: 10.1128/JVI.00256-09
  78. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C, Lifson JD, Allen TM, Carrington M, Altfeld M. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med. 2007;204(12):3027–36. PubMed PMID: 19386717. Pubmed Central PMCID: 2698561. doi: 10.1128/JVI.00256-09
  79. Song R, Lisovsky I, Lebouché B, Routy J-P, Bruneau J, Bernard NF. HIV Protective KIR3DL1/S1-HLA-B Genotypes Influence NK Cell-Mediated Inhibition of HIV Replication in Autologous CD4 Targets. PLoS Pathog. 2014;10(1):e1003867–12. PubMed PMID: 24453969. Pubmed Central PMCID: 3894215. doi: 10.1371/journal.ppat.1003867
  80. Carr WH, Rosen DB, Arase H, Nixon DF, Michaëlsson J, Lanier LL. Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol. 2007;178(2):647–51. PubMed PMID: 17202323. Pubmed Central PMCID: 2561215.
  81. Norman PJ, Abi-Rached L, Gendzekhadze K, Korbel D, Gleimer M, Rowley D, Bruno D, Carrington CVF, Chandanayingyong D, Chang Y-H, Crespí C, Saruhan-Direskeneli G, Fraser PA, Hameed K, Kamkamidze G, Koram KA, Layrisse Z, Matamoros N, Milà J, Park MH, Pitchappan RM, Ramdath DD, Shiau M-Y, Stephens HAF, Struik S, Verity DH, Vaughan RW, Tyan D, Davis RW, Riley EM, Ronaghi M, Parham P. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet. 2007;39(9):1092–9. PubMed PMID: 17694054. doi: 10.1038/ng2111
  82. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 1994;180(4):1235–42. PubMed PMID: 7931060. Pubmed Central PMCID: 2191670.
  83. Gillespie GMA, Bashirova A, Dong T, Mcvicar DW, Rowland-Jones SL, Carrington M. Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res Hum Retroviruses. 2007;23(3):451–5. PubMed PMID: 17411378. doi: 10.1089/aid.2006.0165
  84. O’Connor GMG, Guinan KJK, Cunningham RTR, Middleton DD, Parham PP, Gardiner CMC. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. 2007;178(1):235–41. PubMed PMID: 17182560.
  85. O’Connor GM, Vivian JP, Gostick E, Pymm P, Lafont BAP, Price DA, Rossjohn J, Brooks AG, Mcvicar DW. Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1. J Virol. 2015;89(10):5213–21. PubMed PMID: 25740999. Pubmed Central PMCID: 4442525. doi: 10.1128/JVI.03586-14
  86. Garcia-Beltran WF, Hölzemer A, Martrus G, Chung AW, Pacheco Y, Simoneau CR, Rucevic M, Lamothe-Molina PA, Pertel T, Kim T-E, Dugan H, Alter G, Déchanet-Merville J, Jost S, Carrington M, Altfeld M. Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. Nat Immunol. 2016;17(9):1067–74. PubMed PMID: 27455421. Pubmed Central PMCID: 4992421. doi: 10.1038/ni.3513.
  87. Boudreau JE, Mulrooney TJ, Le Luduec J-B, Barker E, Hsu KC. KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV. J Immunol. 2016;196(8):3398–410. PubMed PMID: 26962229. Pubmed Central PMCID: 4868784. doi: 10.4049/jimmunol.1502469
  88. Hens J, Jennes W, Kestens L. The role of NK cells in HIV-1 protection: autologous, allogeneic or both? AIDS Res Ther. 2016;13(1):15. PubMed PMID: 26997965. Pubmed Central PMCID: 4799629. doi: 10.1186/s12981-016-0099-6
  89. Lisovsky I, Isitman G, Song R, DaFonseca S, Tremblay-McLean A, Lebouché B, Routy J-P, Bruneau J, Bernard NF. A Higher Frequency of NKG2A+ than of NKG2A- NK Cells Responds to Autologous HIV-Infected CD4 Cells irrespective of Whether or Not They Coexpress KIR3DL1. J Virol. 2015;89(19):9909–19. PubMed PMID: 26202228. Pubmed Central PMCID: 4577891. doi: 10.1128/JVI.01546-15
  90. Davis ZB, Cogswell A, Scott H, Mertsching A, Boucau J, Wambua D, Le Gall S, Planelles V, Campbell KS, Barker E. A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog. 2016;12(2):e1005421–2. PubMed PMID: 26828202. Pubmed Central PMCID: 4735451. doi: 10.1371/journal.ppat.1005421
  91. Lisovsky I, Isitman G, Tremblay-McLean A, Song R, DaFonnseca S, Lebouché B, Routy J-P, Bruneau J, Bernard NF. The differential impact of NK cell education via KIR2DL3 and KIR3DL1 on CCL4 secretion in the context of in vitro HIV infection. Clin Exp Immunol. 2016;1–42. PubMed PMID: 27506421. doi: 10.1111/cei.12849
  92. Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest. 2008:1–10. PubMed PMID: 18246204. Pubmed Central PMCID: 2214845. doi: 10.1172/JCI32400
  93. La D, Czarnecki C, El-Gabalawy H, Kumar A, Meyers AFA, Bastien N, Simonsen JN, Plummer FA, Luo M. Enrichment of Variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU Patients: An Exploratory Study. PLoS ONE. 2011;6(12):e29200. PubMed PMID: 22216211. Pubmed Central PMCID: 3247251. doi: 10.1371/journal.pone.0029200
  94. Mendelson M, Tekoah Y, Zilka A, Gershoni-Yahalom O, Gazit R, Achdout H, Bovin NV, Meningher T, Mandelboim M, Mandelboim O, David A, Porgador A. NKp46 O-Glycan Sequences That Are Involved in the Interaction with Hemagglutinin Type 1 of Influenza Virus. J Virol. 2010;84(8):3789–97. PubMed PMID: 20147410. Pubmed Central PMCID: 2849520. doi: 10.1128/JVI.01815-09
  95. Draghi M, Pashine A, Sanjanwala B, Gendzekhadze K, Cantoni C, Cosman D, Moretta A, Valiante NM, Parham P. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. 2007;178(5):2688–98. PubMed PMID: 17312110.
  96. Bar-On Y, Glasner A, Meningher T, Achdout H, Gur C, Lankry D, Vitenshtein A, Meyers AFA, Mandelboim M, Mandelboim O. Neuraminidase-Mediated, NKp46-Dependent Immune-Evasion Mechanism of Influenza Viruses. Cell Rep. 2013;3(4):1044–50. PubMed PMID: 23602571. Pubmed Central PMCID: 3863986. doi: 10.1016/j.celrep.2013.03.034
  97. Narni-Mancinelli E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A, Mahmood S, Gut M, Heath SC, Estellé J, Bertosio E, Vély F, Gastinel LN, Beutler B, Malissen B, Malissen M, Gut IG, Vivier E, Ugolini S. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science. 2012;335(6066):344–8. 2012;335(6066):344-8. PubMed PMID: 22267813. doi: 10.1126/science.1215621
  98. Duev-Cohen A, Bar-On Y, Glasner A, Berhani O, Ophir Y, Levi-Schaffer F, Mandelboim M, Mandelboim O. The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity. Oncotarget. 2016;7(11):13093–105. PubMed PMID: 26919106. Pubmed Central PMCID: 4914344. doi: 10.18632/oncotarget.7597
  99. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, Missale G, Ferrari C, Khakoo SI. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology. 2010;138(4):1536–45. PubMed PMID: 20080094. Pubmed Central PMCID: 4183834. doi: 10.1053/j.gastro.2010.01.006
  100. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little A-M, Alexander GJ, Cramp ME, O’Brien SJ, Rosenberg WMC, Thomas DL, Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685):872–4. PubMed PMID: 15297676. doi: 10.1126/science.1097670
  101. Thoens C, Berger C, Trippler M, Siemann H, Lutterbeck M, Broering R, Schlaak J, Heinemann FM, Heinold A, Nattermann J, Scherbaum N, Alter G, Timm J. KIR2DL3⁺NKG2A⁻ natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs. J Hepatol. 2014 Sep;61(3):475–81. PubMed PMID: 24780303. doi: 10.1016/j.jhep.2014.04.020
  102. Carapito R, Bahram S. Genetics, genomics, and evolutionary biology of NKG2D ligands. Immunol Rev. 2015;267(1):88–116. PubMed PMID: 26284473. doi: 10.1111/imr.12328
  103. Achour A, Baychelier F, Marty M, Debré P, Samuel D, Vieillard V. Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors. Oncoimmunology. 2014;3(5):e28782–3. PubMed PMID: 25050225. Pubmed Central PMCID: 4077860. doi: 10.4161/onci.28782
  104. Rölle A, Brodin P. Immune Adaptation to Environmental Influence: The Case of NK Cells and HCMV. Trends Immunol. Elsevier; 2016;37(3):233–43. PubMed PMID: 26869205. doi: 10.1016/j.it.2016.01.005
  105. Chiesa Della M. Impact of HCMV infection on NK cell development and function after HSCT. Front Immunol. 2013;4:458. PubMed PMID: 24379818. Pubmed Central PMCID: 3861788. doi: 10.3389/fimmu.2013.00458
  106. Gumá MM, Cabrera CC, Erkizia II, Bofill MM, Clotet BB, Ruiz LL, López-Botet MM. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis. 2006;194(1):38–41. PubMed PMID: 16741880. doi: 10.1086/504719
  107. Djaoud Z, David G, Bressollette C, Willem C, Rettman P, Gagne K, Legrand N, Mehlal S, Cesbron A, Imbert-Marcille BM, Retiere C. Amplified NKG2C+ NK Cells in Cytomegalovirus (CMV) Infection Preferentially Express Killer Cell Ig-like Receptor 2DL: Functional Impact in Controlling CMV-Infected Dendritic Cells. J Immunol. 2013;191(5):2708–16. PubMed PMID: 23918974. doi: 10.4049/jimmunol.1301138
  108. Guma M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. 2004;104(12):3664–71. PubMed PMID: 15304389. doi: 10.1182/blood-2004-05-2058
  109. Gumá M, Budt M, Sáez A, Brckalo T, Hengel H, Angulo A, López-Botet M. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood. 2006;107(9):3624–31. PubMed PMID: 16384928. doi: 10.1182/blood-2005-09-3682
  110. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang S-M, Norris PJ, Nixon DF, Lanier LL. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. 2011. pp. 14725–32. PubMed PMID: 21825173. Pubmed Central PMCID: 3169160. doi: 10.1073/pnas.1110900108
  111. Hendricks DW, Balfour HH, Dunmire SK, Schmeling DO, Hogquist KA, Lanier LL. Cutting Edge: NKG2ChiCD57+ NK Cells Respond Specifically to Acute Infection with Cytomegalovirus and Not Epstein-Barr Virus. J Immunol. 2014;192(10):4492-6. PubMed PMID: 24740502. Pubmed Central PMCID: 4013527. doi: 10.4049/jimmunol.1303211
  112. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Verges S, Lanier LL, Weisdorf D, Miller JS. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012;119(11):2665–74. PubMed PMID: 22180440. Pubmed Central PMCID: 3311280. doi: 10.1182/blood-2011-10-386995
  113. Béziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debré P, Björkström NK, Malmberg K-J, Marcellin P, Vieillard V. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol. 2011;42(2):447–57. PubMed PMID: 22105371. doi: 10.1002/eji.201141826
  114. Beziat V, Liu L, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, Retiere C, Sverremark-Ekstrom E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale J, Michaelsson J, Ljunggren HG, Malmberg K-J. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood. 2013;121(14):2678–88. PubMed PMID: 23325834. Pubmed Central PMCID: 3617633. doi: 10.1182/blood-2012-10-459545
  115. Achour A, Baychelier F, Besson C, Arnoux A, Marty M, Hannoun L, Samuel D, Debre P, Vieillard V, the K-GREF Study Group. Expansion of CMV-Mediated NKG2C+ NK Cells Associates with the Development of Specific De Novo Malignancies in Liver-Transplanted Patients. J Immunol. 2014;192(1):503–11. PubMed PMID: 24307732. doi: 10.4049/jimmunol.1301951
  116. Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F, Moretta A. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood. 2012;119(2):399–410. PubMed PMID: 22096237. doi: 10.1182/blood-2011-08-372003
  117. Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, la Cámara de R, Nieto J, López J, Amat P, Garcia-Noblejas A, Bravo D, Clari MÁ, Navarro D. Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. J Med Virol. 2012;84(2):259–67. PubMed PMID: 22170546. doi: 10.1002/jmv.22254
  118. Zhang T, Scott JM, Hwang I, Kim S. Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency. The Journal of Immunology. 2013 Feb 15;190(4):1402–6. PubMed PMID: 23345329. Pubmed Central PMCID: 3623944. doi: 10.4049/jimmunol.1203034
  119. Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, Scott JM, Kamimura Y, Lanier LL, Kim S. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity. 2015;42(3):431–42. Pubmed Central PMCID: 4537797. doi: 10.1016/j.immuni.2015.02.013
  120. Schlums H, Cichocki F, Tesi B, Theorell J, Béziat V, Holmes TD, Han H, Chiang SCC, Foley B, Mattsson K, Larsson S, Schaffer M, Malmberg K-J, Ljunggren H-G, Miller JS, Bryceson YT. Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function. Immunity. 2015;42(3):443–56. PubMed PMID: 25786176. Pubmed Central PMCID: 4612277. doi: 10.1016/j.immuni.2015.02.008
  121. Achour A, Baychelier F, Besson C, Arnoux A, Marty M, Hannoun L, Samuel D, Debré P, Vieillard V, K-GREF Study Group. Expansion of CMV-mediated NKG2C+ NK cells associates with the development of specific de novo malignancies in liver-transplanted patients. J of Immunol. 2014 Jan 1;192(1):503–11. PubMed PMID: 24307732. doi: 10.4049/jimmunol.1301951
  122. Ménard C, Blay J-Y, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile J-F, Le Cesne A, Zitvogel L. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69(8):3563–9. PubMed PMID: 19351841. doi: 10.1158/0008-5472.CAN-08-3807
  123. Di Cocco P, Soker T, Clemente K, Margiotta G, Coletti G, Lombardi L, Orlando G, Famulari A, Pisani F. Cytomegalovirus and gastric cancer after renal transplantation: a possible interplay. Transplant Proc. 2012;44(7):1912–5. PubMed PMID: 22974869. doi: 10.1016/j.transproceed.2012.06.051
  124. Strauss-Albee DM, Blish CA. Human NK Cell Diversity in Viral Infection: Ramifications of Ramification. Front Immunol. 2016;7:66. PubMed PMID: 26973646. Pubmed Central PMCID: 4776076. doi: 10.3389/fimmu.2016.00066
  125. Béziat V, Traherne J, Malmberg J-A, Ivarsson MA, Björkström NK, Retière C, Ljunggren H-G, Michaëlsson J, Trowsdale J, Malmberg K-J. Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation. Eur J Immunol. 2014;44(7):2192–6. PubMed PMID: 24723455. Pubmed Central PMCID: 4282447. doi: 10.1002/eji.201444464
  126. Min-Oo G, Lanier LL. Cytomegalovirus generates long-lived antigen-specific NK cells with diminished bystander activation to heterologous infection. J Exp Med. 2014;211(13):2669–80. PubMed PMID: 25422494. Pubmed Central PMCID: 4267234. doi: 10.1084/jem.20141172
  127. Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y, Best JA, Goldrath AW, Lanier LL, Immunological Genome Project C. Molecular definition of the identity and activation of natural killer cells. Nat Immunol. 2012;13(10):1000–9. PubMed PMID: 22902830. Pubmed Central PMCID: 3572860. doi: 10.1038/ni.2395
  128. Björkström NK, Ljunggren H-G, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016;16(5):310–20. PubMed PMID: 27121652. 10.1038/nri.2016.34
  129. Sojka DK, Tian Z, Yokoyama WM. Tissue-resident natural killer cells and their potential diversity. Semin Immunol. 2014;26(2):127–31. PubMed PMID: 24548893. Pubmed Central PMCID: 4459495. doi: 10.1016/j.smim.2014.01.010
  130. Tang L, Peng H, Zhou J, Chen Y, Wei H, Sun R, Yokoyama WM, Tian Z. Differential phenotypic and functional properties of liver-resident NK cells and mucosal ILC1s. J Autoimmun. 2016;67:29–35. PubMed PMID: 26422992. doi: 10.1016/j.jaut.2015.09.004
  131. Ivanova D, Krempels R, Ryfe J, Weitzman K, Stephenson D, Gigley JP. Review Article NK Cells in Mucosal Defense against Infection. Ivanova D, Krempels R, Ryfe J, Weitzman K, Stephenson D, Gigley JP. NK cells in mucosal defense against infection. Biomed Res Int. 2014;2014:413982. PubMed PMID: 25197644. Pubmed Central PMCID: 4150440. doi: 10.1155/2014/413982
  132. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol. 2012;189(10):5082–8. PubMed PMID: 23077239. Pubmed Central PMCID: 3490031. doi: 10.4049/jimmunol.1201964
  133. Muntasell A, López-Montañés M, Vera A, Heredia G, Romo N, Peñafiel J, Moraru M, Vila J, Vilches C, López-Botet M. NKG2Czygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. Eur J Immunol. 2013;43(12):3268–78. PubMed PMID: 24030638. doi: 10.1002/eji.201343773
  134. Prod’homme V, Griffin C, Aicheler RJ, Wang ECY, McSharry BP, Rickards CR, Stanton RJ, Borysiewicz LK, López-Botet M, Wilkinson GWG, Tomasec P. The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells. J Immunol. 2007;178(7):4473–81. PubMed PMID: 17372005. Pubmed Central PMCID: 2843079.
  135. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E, Porgador A, Honigman A, Plachter B, Mevorach D, Wolf DG, Mandelboim O. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol. 2005;6(5):515–23. PubMed PMID: 15821739. doi: 10.1038/ni1190
  136. Martini F, Agrati C, D’Offizi G, Poccia F. HLA-E up-regulation induced by HIV infection may directly contribute to CD94-mediated impairment of NK cells. Int J Immunopathol Pharmacol. 2005;18(2):269–76. PubMed PMID: 15888249.
  137. Zhou J, Amran FS, Kramski M, Angelovich TA, Elliott J, Hearps AC, Price P, Jaworowski A. An NK Cell Population Lacking FcRgamma Is Expanded in Chronically Infected HIV Patients. J Immunol. 2015;194(10):4688–97. PubMed PMID: 25855354. doi: 10.4049/jimmunol.1402448
  138. Merino AM, Dugast A-S, Wilson CM, Goepfert PA, Alter G, Kaslow RA, Tang J. KIR2DS4 Promotes HIV-1 Pathogenesis: New Evidence from Analyses of Immunogenetic Data and Natural Killer Cell Function. Unutmaz D, editor. PLoS ONE. 2014;9(6):e99353. PubMed PMID: 24901871. Pubmed Central PMCID: 4047121. doi: 10.1371/journal.pone.0099353
  139. Jiang Y, Chen O, Cui C, Zhao B, Han X, Zhang Z, Liu J, Xu J, Hu Q, Liao C, Shang H. KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors. BMC Infect Dis. BioMed Central; 2013;13(1):405. PubMed PMID: 24059286. Pubmed Central PMCID: 3766012. doi: 10.1186/1471-2334-13-405
  140. Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, Bernard NF. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol. 2010;184(4):2057–64. PubMed PMID: 20061407. doi: 10.4049/jimmunol.0902621
  141. Parsons MS, Wren L, Isitman G, Navis M, Stratov I, Bernard NF, Kent SJ. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol. 2012;86(8):4488–95. PubMed PMID: 22345455. Pubmed Central PMCID: 3318670. doi: 10.1128/JVI.06112-11
  142. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, Oniangue-Ndza C, Martin M, Li B, Khakoo SI, Carrington M, Allen TM, Altfeld M. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature. 2011;476(7358):96–100. PubMed PMID: 21814282. Pubmed Central PMCID: 3194000. doi: 10.1038/nature10237
  143. Körner C, Granoff ME, Amero MA, Sirignano MN, Vaidya SA, Jost S, Allen TM, Rosenberg ES, Altfeld M. Increased frequency and function of KIR2DL1-3 +NK cells in primary HIV-1 infection are determined by HLA-Cgroup haplotypes. Eur J Immunol. 2014;44(10):2938–48. PubMed PMID: 25043727. Pubmed Central PMCID: 4197106. doi: 10.1002/eji.201444751
  144. Altfeld M, Gale M Jr. Innate immunity against HIV-1 infection. Nat Immunol. 2015;16(6):554–62. PubMed PMID: 25988887. doi: 10.1038/ni.3157
  145. Chavan VR, Ahir S, Ansari Z, Samant-Mawani P, Nanavati R, Mehta P, Mania-Pramanik J. Diversity in KIR gene repertoire in HIV-1 exposed infected and uninfected infants: A study from India. J Med Virol. 2015;88(3):417–25. PubMed PMID: 26255774. doi: 10.1002/jmv.24348
  146. Hölzemer A, Thobakgale CF, Jimenez Cruz CA, Garcia-Beltran WF, Carlson JM, van Teijlingen NH, Mann JK, Jaggernath M, Kang S-G, Körner C, Chung AW, Schafer JL, Evans DT, Alter G, Walker BD, Goulder PJ, Carrington M, Hartmann P, Pertel T, Zhou R, Ndung’u T, Altfeld M. Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa. PLoS Med. 2015;12(11):e1001900; discussion e. PubMed PMID: 26575988. Pubmed Central PMCID: 4648589. doi: 10.1371/journal.pmed.1001900
  147. Scott-Algara D, Arnold V, Didier C, Kattan T, Pirozzi G, Barré-Sinoussi F, Pancino G. The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells. PLoS One. 2008;3(4):e1975. PubMed PMID: 18398485. Pubmed Central PMCID: 2276866. doi: 10.1371/journal.pone.0001975
  148. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, Moretta A, Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol. 2003;33(9):2410-8. PubMed PMID: 12938217. doi: 10.1002/eji.200324141
  149. Schwartz O. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med. 1996;2(3):338–42. PubMed PMID: 8612235.
  150. Cerboni C, Neri F, Casartelli N, Zingoni A, Cosman D, Rossi P, Santoni A, Doria M. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol. 2007;88(Pt 1):242–50. PubMed PMID: 17170457. doi: 10.1099/vir.0.82125-0
  151. Galaski J, Ahmad F, Tibroni N, Pujol FM, Müller B, Schmidt RE, Fackler OT. Cell Surface Downregulation of NK Cell Ligands by Patient-Derived HIV-1 Vpu and Nef Alleles. J Acquir Immune Defic Syndr. 2016;72(1):1–10. PubMed PMID: 26656785. doi: 10.1097/QAI.0000000000000917
  152. Parsons MS, Richard J, Lee WS, Vanderven H, Grant MD, Finzi A, Kent SJ. NKG2D acts as a co-receptor for natural killer cell-mediated anti-HIV-1 antibody-dependent cellular cytotoxicity. AIDS Res Hum Retroviruses. 2016. PubMed PMID: 27487965. doi: 10.1089/AID.2016.0099
  153. Tomescu C, Mavilio D, Montaner LJ. Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D. AIDS. 2015;29(14):1767–73. PubMed PMID: 26372382. Pubmed Central PMCID: 4571461. doi: 10.1097/QAD.0000000000000777
  154. Bisio F, Bozzano F, Marras F, Di Biagio A, Moretta L, De Maria A. Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. Immunol Lett. 2013;152(1):16-24. PubMed PMID: 23538009. doi: 10.1016/j.imlet.2013.03.003
  155. Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, Barker E. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe. 2010;8(5):397–409. PubMed PMID: 21075351. Pubmed Central PMCID: 3005698. doi: 10.1016/j.chom.2010.10.008
  156. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, Moretta A, Mavilio D. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood. 2009;114(18):3822–30. PubMed PMID: 19710502. Pubmed Central PMCID: 2773483. doi: 10.1182/blood-2009-06-226332
  157. Björkström NK, Svensson A, Malmberg K-J, Eriksson K, Ljunggren H-G. Characterization of Natural Killer Cell Phenotype and Function during Recurrent Human HSV-2 Infection. Zimmer J, editor. PLoS ONE. 2011;6(11):e27664. PubMed PMID: 22110712. Pubmed Central PMCID: 3216993. doi: 10.1371/journal.pone.0027664
  158. Campbell TM, McSharry BP, Steain M, Slobedman B, Abendroth A. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection. Hutt-Fletcher L, editor. Journal of Virology. 2015;89(15):7932–43. PubMed PMID: 25995251. Pubmed Central PMCID: 4505661. doi: 10.1128/JVI.00292-15
  159. Ishido S, Choi JK, Lee BS, Wang C, DeMaria M, Johnson RP, Cohen GB, Jung JU. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi’s sarcoma-associated herpesvirus K5 protein. Immunity. 2000;13(3):365–74. PubMed PMID: 11021534.
  160. Bjorkstrom NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, Michaelsson J, Malmberg K-J, Klingstrom J, Ahlm C, Ljunggren HG. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med. 2011;208(1):13–21. PubMed PMID: 21173105. Pubmed Central PMCID: 3023129. doi: 10.1084/jem.20100762
  161. Petitdemange C, Wauquier N, Devilliers H, Yssel H, Mombo I, Caron M, Nkoghé D, Debré P, Leroy E, Vieillard V. Longitudinal Analysis of Natural Killer Cells in Dengue Virus-Infected Patients in Comparison to Chikungunya and Chikungunya/Dengue Virus-Infected Patients. PLoS Negl Trop Dis. 2016;10(3):e0004499. PubMed PMID: 26938618. Pubmed Central PMCID: 4777550. doi: 10.1371/journal.pntd.0004499
  162. Beltrán D, Lopez-Vergès S. NK Cells During Dengue Disease and Their Recognition of Dengue Virus-Infected Cells. Front Immunol. Frontiers; 2014;5(9599):192.
  163. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell KS, Rager-Zisman B, Despres P, Porgador A. NKp44 Receptor Mediates Interaction of the Envelope Glycoproteins from the West Nile and Dengue Viruses with NK Cells. J Immunol. 2009;183(4):2610-21. PubMed PMID: 19635919. Pubmed Central PMCID: 2768489. doi: 10.4049/jimmunol.0802806